Genentech CEO snags $14M in pay as shares swoon

Genentech CEO Arthur Levinson (photo) scooped up close to $14 million in compensation last year, even as its stock price slid in the face of slowing cancer therapy revenues. Levinson declined a raise, keeping his income under the million-dollar mark, and there was $2.7 million in bonuses for meeting his goals for the year. According to a review by the AP, Levinson also took home about $10 million in stock options and perks that included $97,375 for home security.

- read the AP analysis

ALSO: Johnson & Johnson honcho Bill Weldon (photo) nabbed a 22 percent hike in compensation in 2007. Between base salary of $1.73 million, incentive pay of $9.19 million, plus stock awards and options and various miscellaneous perks, he raked in $25.1 million in compensation. Report

Related Articles:
Genentech successes pay off big for CEO. Report
Genentech touts pipeline prospects as doubts fester. Report
Genentech fights to keep edge in drug development. Report
Genentech hiring researchers in big R&D push. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.